Literature DB >> 15215883

Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor.

K-W Peng1, P D Holler, B A Orr, D M Kranz, S J Russell.   

Abstract

The T-cell receptor (TCR) determines the specificity of T-cell recognition by binding to peptide fragments of intracellular proteins presented at the cell surface in association with molecules of the major histocompatibility complex (MHC). Engagement of the TCR by its cognate peptide/MHC ligand, with appropriate co-stimulatory signals, leads to activation of T-cell effector functions. Here we show that the attachment proteins of attenuated measles viruses, engineered to display a high-affinity single-chain TCR (scTCR), can recognize and bind to specific peptide-MHC complexes and thereby mediate targeted virus-cell entry and cell-to-cell fusion. Using the 2C TCR and its peptide/MHC ligand (SIYRYYGL/mouse K(b)), we show that a scTCR grafted onto the measles virus H protein confers new specificity to virus entry and cell fusion. The efficiency of TCR-mediated virus entry was dependent on the number of peptide/MHC complexes expressed on the target cells, increasing progressively above densities higher than 2500 complexes per cell. This work introduces a new paradigm for targeting virus entry and membrane fusion by extending the repertoire of targets to specific peptide-MHC ligands and offering a novel quantitative readout for the cellular expression of peptide-MHC complexes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215883     DOI: 10.1038/sj.gt.3302286

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  13 in total

1.  High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics.

Authors:  Stephen P Persaud; David L Donermeyer; K Scott Weber; David M Kranz; Paul M Allen
Journal:  Mol Immunol       Date:  2010-03-23       Impact factor: 4.407

2.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

3.  For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough).

Authors:  Stephen J Russell
Journal:  Mol Ther       Date:  2018-07-18       Impact factor: 11.454

Review 4.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

5.  Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entry.

Authors:  Matthew K Ennis; Chunling Hu; Shruthi K Naik; Louay K Hallak; Kah Whye Peng; Stephen J Russell; David Dingli
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 6.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

Review 7.  Measles virus for cancer therapy.

Authors:  S J Russell; K W Peng
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

8.  Antibody neutralization of retargeted measles viruses.

Authors:  Patrycja J Lech; Roland Pappoe; Takafumi Nakamura; Gregory J Tobin; Peter L Nara; Stephen J Russell
Journal:  Virology       Date:  2014-03-14       Impact factor: 3.616

Review 9.  Measles to the Rescue: A Review of Oncolytic Measles Virus.

Authors:  Sarah Aref; Katharine Bailey; Adele Fielding
Journal:  Viruses       Date:  2016-10-22       Impact factor: 5.048

Review 10.  Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function.

Authors:  Michael E Birnbaum; Shen Dong; K Christopher Garcia
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.